CRNX (Crinetics Pharmaceuticals) Short Percentage of Float


CRNX Crinetics Pharmaceuticals Inc CRNX
41 GF Score
Price $42.02
GF Value $717.51
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CRNX vs CPRX, NAMS, RCUS: Short Percentage of Float Comparison

For the Biotechnology subindustry, Crinetics Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crinetics Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Crinetics Pharmaceuticals's Short Percentage of Float falls into.


CRNX
41GF Score
Crinetics Pharmaceuticals Inc CRNX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Crinetics Pharmaceuticals (CRNX) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of $42.02 is trading 94.1% below its estimated GF Value™ of $717.51. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CRNX:

  • Short Percentage of Float:
  • GF Value™: $717.51 vs. price of $42.02 (94.1% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the CRNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crinetics Pharmaceuticals Business Description

Other Exchanges 6Z4:Germany
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
41GF Score

Get the complete analysis for CRNX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.02
Price
$717.51
GF Value